Leukemic ocular involvement arises from direct infiltration, hematologic derangements (anemia, thrombocytopenia, ...

Cancer care in 2026 now relies on immunotherapy, targeted therapy, and multimodality treatment, even in early stages, ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, ...

Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

The Students of St. Margaret School in Bel Air donated 174 pairs of new pajamas to the Casey Cares Foundation. To date, the ...

Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, ...

For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the journey can be overwhelming. Treatments are often intense, and the risk of relapse looms large.

Dr. Zaker Schwabkey is a physician and an Assistant Professor of Medicine and Clinical Investigator in the Division of Hematology & Hematologic Malignancies at the University of Utah’s Huntsman Cancer ...

Genient, a Noida-based genomics and molecular diagnostics company founded in 2017, is strengthening India's precision ...

Medically reviewed by Lindsay Cook, PharmD Mixing grapefruit, whether as a juice or in a dietary supplement, with some ...

Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance.